Novavax launches trial for combo COVID-19/flu vaccine


Novavax announced it will begin testing its combined influenza and COVID-19 vaccine in an early-stage trial that will be conducted in Australia with 640 healthy adult participants who have either received an authorized COVID-19 vaccine before the trial or recovered from a coronavirus infection. Participants will be given a combination of NVX-CoV2373, Novavax's vaccine candidate, and NanoFlu, the company's influenza vaccine, together with a vaccine booster or an adjuvant.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.